NIKIHealthcare · BiotechnologyNIKI Stock Forecast: Niki Biosolutions, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 1 Aug 2026 — in the weakest quartile.
NIKI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Niki Biosolutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Value (5): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Niki Biosolutions, Inc. — and when they’d sell — is the membership.
NIKI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NIKI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2022 | HC Wainwright & Co. | Initiates | Buy | $8.00 |
| 2 Apr 2019 | China Renaissance | Initiates | Buy | $22 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NIKI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Niki Biosolutions, Inc. (NIKI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 2.8×
- Price / sales
- —
- Price / book
- 0.3×
- EV / EBITDA
- 0.9×
Cheaper than 68% of US stocks
Cheaper than 87% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −10.8%
- Return on assets
- −6.5%
- Dividend yield
- —
Higher than 35% of US stocks
Higher than 30% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NIKI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NIKI appears on the weeks it earns a place.
Frequently asked questions about NIKI stock
How does Ticker Nerd's model rank NIKI?
As at 1 Aug 2026, Niki Biosolutions, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
What is the NIKI stock forecast for 2030?
No analyst covering Niki Biosolutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NIKI are extrapolating price history, which says nothing about the business.
How has NIKI stock performed over the past year?
Niki Biosolutions, Inc. returned -30.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Niki Biosolutions, Inc. do?
Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on therapeutic and diagnostic solutions for serious diseases with unmet medical needs.
About Niki Biosolutions, Inc.
Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on therapeutic and diagnostic solutions for serious diseases with unmet medical needs. Through its subsidiaries, the company is primarily engaged in the discovery, development, and commercialization of drug candidates targeting oncology and infectious diseases, alongside molecular diagnostics for brain health and pathogen detection. Its therapeutic pipeline includes SACT-1, a repurposed small-molecule candidate in early-stage clinical development for neuroblastoma and other cancers, and ALS-4, a small molecule being evaluated for bacterial infections such as those caused by Staphylococcus aureus, including resistant strains. In diagnostics, Niki BioSolutions incorporates a proprietary microRNA-based platform designed to assess brain health, as well as the PathsDx Test, a rapid molecular pathogen identification technology. Headquartered in Princeton, New Jersey, with historical operations in the United Kingdom, the company today operates within the biotechnology and healthcare sectors, serving global pharmaceutical and clinical research markets through its specialized therapeutics and advanced diagnostic solutions.
CEO Mr. Chung Yuen Huen · 1 employees · United States · https://www.aptorumgroup.com